

Osteomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/OE0D58F34E21EN.html>

Date: March 2022

Pages: 35

Price: US\$ 2,000.00 (Single User License)

ID: OE0D58F34E21EN

Abstracts

Osteomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteomyelitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Osteomyelitis (Infectious Disease) pipeline landscape.

Osteomyelitis is an infection in a bone. Infections can reach a bone by traveling through the bloodstream or spreading from nearby tissue. Symptoms include fever, pain in the area of the infection, swelling, warmth and redness over the area of the infection and irritability. Risk factors bone fracture, sickle cell disease, chemotherapy, diabetes and peripheral arterial disease. Treatment includes surgery and oral antibiotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteomyelitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Osteomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and

press releases.

The Osteomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Osteomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 2 and 6 respectively.

Osteomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Osteomyelitis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Osteomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Osteomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Osteomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Osteomyelitis (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Osteomyelitis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Osteomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Osteomyelitis - Overview

Osteomyelitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Osteomyelitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Osteomyelitis - Companies Involved in Therapeutics Development

Adaptive Phage Therapeutics Inc

BioVinc LLC

ContraFect Corp

Debiopharm International SA

Integrated BioTherapeutics Inc

Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd

Nabriva Therapeutics Plc

Sonoran Biosciences Inc

Osteomyelitis - Drug Profiles

(tobramycin + vancomycin SR) - Drug Profile

Product Description

Mechanism Of Action

History of Events

afabycin - Drug Profile

Product Description

Mechanism Of Action

History of Events

Biologics for Diabetic Foot Osteomyelitis - Drug Profile

Product Description

Mechanism Of Action

History of Events

BV-600022 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ceforanide - Drug Profile

Product Description

Mechanism Of Action

CF-296 - Drug Profile

Product Description

Mechanism Of Action

History of Events

lefamulin acetate - Drug Profile

Product Description

Mechanism Of Action

History of Events

TPH-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Osteomyelitis - Dormant Projects

Osteomyelitis - Product Development Milestones

Featured News & Press Releases

Jul 19, 2021: ContraFect announces multiple publications on CF-296 demonstrating potent in vivo antimicrobial activity

Mar 10, 2021: Adaptive Phage Therapeutics announces FDA clearance of IND application for PhageBank in treatment of diabetic foot osteomyelitis

Dec 11, 2017: Telephus Biosciences Appoints Patrick Vink, M.D., MBA, William Boyle, Ph.D., and Richard Proctor, M.D., as Company Advisors

Apr 08, 2016: Debiopharm International to present the latest findings on Debio 1450 at ECCMID

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Osteomyelitis, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Osteomyelitis - Pipeline by Adaptive Phage Therapeutics Inc, 2022
Osteomyelitis - Pipeline by BioVinc LLC, 2022
Osteomyelitis - Pipeline by ContraFect Corp, 2022
Osteomyelitis - Pipeline by Debiopharm International SA, 2022
Osteomyelitis - Pipeline by Integrated BioTherapeutics Inc, 2022
Osteomyelitis - Pipeline by Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, 2022
Osteomyelitis - Pipeline by Nabriva Therapeutics Plc, 2022
Osteomyelitis - Pipeline by Sonoran Biosciences Inc, 2022
Osteomyelitis - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Osteomyelitis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Osteomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/OE0D58F34E21EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OE0D58F34E21EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

